Lake Forest, CA, June 17, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company is the preferred cryogenic logistics provider to CaRE Arthritis (“CaRE”).
Cryoport’s comprehensive cryogenic logistics solutions will support CaRE Arthritis and their efforts in the development of personalized care options for arthritis. Cryoport’s validated solutions provide integrity for temperature sensitive shipments supporting patient access for CaRE Arthritis research and development efforts. Cryoport offers a global network for greater safety and speed of the delivery.
CaRE Arthritis, based in Alberta, Canada, is an academic research organization that supports research and education for arthritis to patients and medical professionals, with an emphasis on the growing field of personalized medicine. The people of CaRE specialize in the development and application of biomarkers and medical imaging to further the advancement of the understanding of the disease. Biomarkers can play a critical role in identifying the severity of arthritic patients as well as their response to treatment.
Dr. Walter Maksymowych, Chief Medical Officer of CaRE Arthritis, stated, “The development and application of new imaging and biomarker technologies is an essential step to bringing the concept of personalized medicine to reality in the day-to-day management of arthritis. With the support of Cryoport’s cold chain logistics, we are working tirelessly to better understand and efficiently treat the disease.”
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, “We look forward to working with CaRE Arthritis to help them advance their research efforts. We offer comprehensive as well as best-in-class cryogenic solutions to an industry that needs reliability in order to accelerate forward. Cryoport is being recognized as a critical partner to the research community from a wide range of organizations.”
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.Investor Contacts:
Todd Fromer / Garth Russell
email@example.com / firstname.lastname@example.org
P: 1 212-682-6300